Merck KGaA (OTCMKTS:MKGAF) Raised to “Sell” at ValuEngine

Merck KGaA (OTCMKTS:MKGAF) was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued on Monday, ValuEngine reports.

Merck KGaA stock traded up $0.24 during midday trading on Monday, hitting $117.14. 12 shares of the company’s stock were exchanged, compared to its average volume of 810. Merck KGaA has a 12-month low of $96.00 and a 12-month high of $117.14. The company has a debt-to-equity ratio of 0.29, a quick ratio of 0.68 and a current ratio of 0.94. The stock has a market cap of $14.99 billion, a price-to-earnings ratio of 20.45 and a beta of 0.72. The firm’s 50 day simple moving average is $111.75 and its 200 day simple moving average is $106.76.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Read More: Bond

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.